University of Ulsan Foundation for Industry Cooperation

The Asan Foundation

Wellmarker Bio Co., Ltd.

Yong Sang Hong

Seung Woo Hong

Jai Hee Moon

Dong Hoon Jin

Jae Sik Shin

Eun Young Lee

Seul Gee Lee

Dae Hee Lee

Eun Kyung Choi

Jeong Hee Kim

Seong Joon Park

Seung Mi Kim

Jung Shin Lee

Seung Hee Ha

Bong Cheol Kim

Kyu Pyo Kim

Kyung Ah Jung

Bong Choel Kim

Jae Lyun Lee

Ky Youb Nam

Jin Sun Kim

Ha Reum Lee

Eun Kyoung Choi

Ih Yeon Hwang

Soo A Jung

The present disclosure relates to a new biomarker for predicting susceptibility to an EGFR-targeted agent and a use thereof, and more particularly, provides a biomarker for predicting susceptibility to an EGFR (Epidermal Growth Factor Receptor)-targeted agent, comprising a RON (Recepteur d'Origine Nantais) gene; a composition for predicting susceptibility to the EGFR-targeted agent, comprising an agent which measures a gene expression level of the biomarker; or an expression or activity level of a protein thereof; a composition for enhancing the susceptibility to the EGFR-targeted agent, comprising an inhibitor of the expression of the gene or the expression or activity of the protein of the gene as active ingredients; a kit for predicting the susceptibility to the EGFR-targeted agent, comprising the composition; and a method for predicting the susceptibility to the EGFR-targeted agent. According to the present disclosure, since an effect of predicting the susceptibility to the EGFR-targeted agent is excellent in a colon cancer, the present disclosure may be useful in the treatment of the colon cancer.

Biomarker for predicting sensitivity to EGFR-targeting agent, and use thereof

The present invention relates to a composition for treatment or metastasis suppression of cancers which includes a p34 expression inhibitor or activity inhibitor as an active ingredient. According to the present invention, the p34 protein knock-down causes monoubiquitination of PTEN and accordingly nuclear localization of PTEN is induced, as a result, an Akt pathway which is related to survival, proliferation, invasive properties and metastatic properties of tumors is inhibited, and thus there is an effect of significantly reducing clonogenic potential and tumor forming potential of various cancer cells which simultaneously express PTEN and NEDD4-1. Consequently, the p34 gene expression inhibitor or p34 protein activity inhibitor according to the present invention can be effectively used as a treatment agent or a metastasis suppression agent for cancers.

Composition for treatment or metastasis suppression of cancers which includes p34 expression inhibitor or activity inhibitor as active ingredient

Growing community of inventors

Seoul, South Korea

Yong Sang Hong